#1 Clinical Trials Search in Europe

BENZYLPENICILLIN PROCAINE

Benzylpenicillin procaine, also known as procaine penicillin, is an antibiotic medication that combines benzylpenicillin with procaine to create a depot formulation. This combination allows for prolonged release of the antibiotic, extending its duration of action. Clinical trials involving benzylpenicillin procaine are exploring its efficacy in treating various infections, from sepsis in young infants to Staphylococcus aureus bacteremia and syphilis. This article examines the current research on benzylpenicillin procaine in clinical trials, including its applications, dosing regimens, and comparative effectiveness against other antibiotics.

Table of Contents

What is Benzylpenicillin Procaine?

Benzylpenicillin procaine is an antibiotic medication that belongs to the penicillin group of antibiotics. It is also known as procaine penicillin or penicillin G procaine. This antibiotic is a combination of benzylpenicillin (also called penicillin G) and procaine, which is a local anesthetic. The procaine component slows the release of penicillin into the bloodstream, allowing the antibiotic to remain active in the body for a longer period[1].

The medication is formulated for intramuscular (IM) injection, which means it is injected directly into a muscle. This administration method allows for a sustained release of the medication, providing an extended duration of action compared to standard benzylpenicillin[2].

How It Works

Benzylpenicillin procaine works by interfering with the cell wall formation of bacteria. Specifically, it targets the peptidoglycan layer of bacterial cell walls, which is essential for bacterial survival. By disrupting this process, the antibiotic weakens the bacterial cell wall, causing it to rupture under osmotic pressure, which leads to bacterial death[1].

The procaine component doesn’t contribute to the antibacterial action but rather helps to:

  • Reduce pain at the injection site
  • Slow the release of penicillin into the bloodstream
  • Extend the duration of action of the antibiotic

This extended-release property is particularly useful in situations where maintaining a consistent level of antibiotic in the bloodstream is important for effective treatment[3].

Medical Uses

Benzylpenicillin procaine is used to treat a variety of bacterial infections. Based on clinical trials, it has shown effectiveness in treating the following conditions[1][4]:

Infections in Young Infants

Benzylpenicillin procaine is used in the treatment of serious bacterial infections in young infants, particularly in high neonatal mortality settings. It’s especially valuable in areas where hospital referral might be refused by families, allowing for outpatient clinic-based therapy[1].

Staphylococcus Aureus Infections

Recent research has examined the use of benzylpenicillin for treating penicillin-susceptible Staphylococcus aureus (PSSA) infections, including bloodstream infections (bacteremia). Some studies suggest it may be superior to other antibiotics like flucloxacillin for these specific infections due to its lower minimum inhibitory concentration (MIC) distribution[5].

Syphilis

Benzylpenicillin and its derivatives (including benzathine benzylpenicillin) are considered the standard treatment for syphilis, an infection caused by the bacterium Treponema pallidum. It’s particularly valuable for treating syphilis in pediatric populations[6].

Pneumonia

Benzylpenicillin is used in treating certain types of pneumonia, particularly in intensive care unit (ICU) settings. Studies are investigating optimal dosing regimens to maximize antibiotic effectiveness for pneumonia treatment[3].

Complicated Urinary Tract Infections

In some cases, benzylpenicillin may be used as part of the treatment for complicated urinary tract infections, particularly when there is a need for additional coverage against certain bacteria like Enterococcus[7].

Other Bacterial Infections

Benzylpenicillin procaine is also used in treating:

  • Sepsis (blood infection)
  • Various skin and soft tissue infections
  • Some cases of bacterial vaginosis or urogenital infections

Dosage and Administration

Benzylpenicillin procaine is typically administered as an intramuscular (IM) injection. The dosage varies depending on the condition being treated, the patient’s age, weight, and the severity of the infection[1][3].

Common Dosages:

  • For young infants with serious bacterial infections: 50,000 IU/kg by intramuscular injection once daily for 7 days (often combined with gentamicin)[1]
  • For Staphylococcus aureus infections in adults: Typically 1.2g IV every 6 hours, with adjustments for severe infections up to 2.4g every 4-6 hours[5]
  • For pediatric complicated urinary tract infections: 30 mg/kg (maximum 1.2 g) every 6 hours, with higher doses of up to 60 mg/kg (maximum 2.4 g) every 4-6 hours for severe infections[7]

In many clinical trials, benzylpenicillin procaine is used in combination with other antibiotics like gentamicin to provide broader coverage against various bacteria[1].

Administration Considerations:

  • Intramuscular injections should be administered by healthcare professionals
  • The injection site should be rotated for multiple doses
  • The medication is not suitable for intravenous (IV) use in its procaine form
  • For some conditions, IV benzylpenicillin (without procaine) may be preferred

It’s important to note that dosages are always determined by healthcare providers based on individual patient factors, the specific infection being treated, and local antibiotic guidelines[3].

Effectiveness in Treatment

Clinical trials have shown that benzylpenicillin procaine is effective in treating various bacterial infections. Its effectiveness depends on several factors, including the type of bacteria causing the infection, the site of infection, and the patient’s overall health[1][5].

For Young Infant Infections:

Research indicates that outpatient treatment with benzylpenicillin procaine and gentamicin for 7 days can be as effective as other antibiotic regimens for young infants with serious bacterial infections. This has important implications for areas where hospital care is limited or refused by families[1].

For Staphylococcus Aureus Infections:

Some studies suggest that benzylpenicillin may be superior to other anti-staphylococcal penicillins (like flucloxacillin) for treating penicillin-susceptible Staphylococcus aureus infections. This potential advantage is attributed to benzylpenicillin’s lower minimum inhibitory concentration (MIC) distribution and higher levels of free non-protein-bound drug concentration in the plasma[5].

Pharmacokinetic Considerations:

Recent research is exploring how benzylpenicillin behaves in different patient populations, particularly in critically ill patients. Studies are investigating optimal dosing strategies to ensure effective concentrations at the site of infection, such as in the lungs for pneumonia patients[3].

New technologies, such as biosensor-guided closed-loop control systems, are being developed to optimize benzylpenicillin delivery and maintain effective blood concentrations[8].

Possible Side Effects

Like all medications, benzylpenicillin procaine can cause side effects. While not everyone experiences side effects, it’s important to be aware of possible reactions[3][5]:

Common Side Effects:

  • Pain or discomfort at the injection site – Due to the intramuscular administration
  • Mild allergic reactions – Such as skin rash, itching, or hives
  • Gastrointestinal disturbances – Including nausea, vomiting, or diarrhea

Serious Side Effects (Less Common):

  • Severe allergic reactions (anaphylaxis) – A medical emergency characterized by difficulty breathing, swelling of the face/throat, and severe rash
  • Blood disorders – Such as reduced blood cell counts
  • Kidney problems – Especially with prolonged use or in patients with pre-existing kidney issues
  • Liver dysfunction – Manifesting as yellowing of the skin/eyes (jaundice) or abnormal liver function tests
  • Nervous system reactions – Particularly with high doses or in patients with kidney problems

Clinical trials investigating benzylpenicillin include monitoring for adverse events as important secondary outcomes. These studies help to better understand the safety profile of the medication in different patient populations[5].

Special Considerations:

Patients with a history of penicillin allergy should not receive benzylpenicillin procaine or any other penicillin-based antibiotic. It’s crucial to inform your healthcare provider about any previous allergic reactions to medications[3].

Comparison with Other Antibiotics

Understanding how benzylpenicillin procaine compares to other antibiotics can help patients better understand their treatment options[1][5].

Benzylpenicillin vs. Flucloxacillin for Staphylococcus Aureus:

Research is investigating whether benzylpenicillin might be superior to flucloxacillin for treating penicillin-susceptible Staphylococcus aureus infections. The PANFLUTE trial is specifically examining this question, with preliminary data suggesting potential benefits of benzylpenicillin due to its lower MIC distribution and higher levels of free drug in plasma[5].

Benzylpenicillin Procaine vs. Alternative Regimens for Infant Infections:

Clinical trials have compared intramuscular procaine penicillin and gentamicin (given for 7 days) to alternative regimens including:

  • Injectable gentamicin once daily and oral amoxicillin twice daily for seven days
  • Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days

These studies aim to identify equally effective but potentially simpler treatment options for young infants with serious bacterial infections[1].

Benzylpenicillin vs. Amoxicillin for Syphilis:

While benzathine benzylpenicillin (a long-acting form) remains the standard treatment for syphilis, research is exploring whether oral amoxicillin could be an effective alternative, particularly in pediatric populations where intramuscular injections may be more challenging[6].

Key Differences:

  • Spectrum of activity: Benzylpenicillin has a narrower spectrum compared to many newer antibiotics, making it more targeted but potentially less effective against certain bacteria
  • Administration: Procaine penicillin requires intramuscular injection, while many newer antibiotics can be given orally or intravenously
  • Duration of action: The procaine component provides a longer duration of action compared to standard benzylpenicillin
  • Resistance patterns: Some bacteria have developed resistance to penicillins, but certain strains remain susceptible to benzylpenicillin

Current Research and Innovations

Several ongoing clinical trials and research initiatives are exploring new applications and administration methods for benzylpenicillin procaine and related compounds[3][8].

Closed-loop Control of Penicillin Delivery:

Innovative research is exploring the use of biosensor technology linked with closed-loop control systems for automated delivery of benzylpenicillin. This approach aims to maintain optimal antibiotic concentrations in the blood, potentially improving treatment outcomes while minimizing side effects[8].

Optimized Dosing for Pneumonia in ICU Patients:

The PNEUDOS study is investigating optimal dosing regimens for various antibiotics, including benzylpenicillin, in intensive care unit patients with pneumonia. This research aims to define personalized dosing approaches that can maximize antibiotic effectiveness by achieving therapeutic concentrations at the infection site (epithelial lining fluid in the lungs)[3].

Comparative Effectiveness Trials:

Several trials are comparing benzylpenicillin to other antibiotics for specific infections:

  • The PANFLUTE trial is comparing benzylpenicillin to flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections[5]
  • Another study is comparing oral amoxicillin to benzathine benzylpenicillin for syphilis treatment[6]
  • Research in pediatric urinary tract infections is exploring the use of single-dose vs. multiple-dose regimens including benzylpenicillin[7]

These studies will provide valuable information about the most effective ways to use benzylpenicillin procaine and related antibiotics in different clinical scenarios, potentially leading to improved treatment protocols and patient outcomes.

Aspect Details
Primary Uses in Clinical Trials – Treatment of sepsis in young infants (0-59 days)
– Management of serious bacterial infections in community settings
– Treatment of penicillin-susceptible Staphylococcus aureus bacteremia
– Component in simplified antibiotic regimens where hospital care is refused
Common Dosing Regimens – For infants: 50,000 IU/kg intramuscular injection once daily
– Often combined with gentamicin (5 mg/kg) for broader coverage
– Typically administered for 7 days for serious infections
– May be used for 2 days followed by oral antibiotics in some protocols
Comparative Studies – Compared with amoxicillin plus gentamicin combinations
– Compared with flucloxacillin for Staphylococcus aureus infections
– Studied as alternative to hospital-based care in resource-limited settings
– Evaluated against benzathine penicillin in some trials
Theoretical Advantages – Once-daily dosing improving adherence
– Lower MIC for certain bacteria compared to alternative antibiotics
– Higher levels of free non-protein-bound plasma drug concentrations
– May be superior for penicillin-susceptible S. aureus infections
Administration Methods – Primarily through intramuscular injection
– Slow release from injection site providing extended activity
– Sometimes part of hybrid regimens (beginning with injections, followed by oral antibiotics)
– Used in both hospital and community-based treatment settings
Outcome Measures in Trials – Treatment failure rates
– Time to resolution of fever/symptoms
– Relapse or recurrence of infection
– Adverse events including phlebitis and kidney/liver function changes
– In some trials, DOOR (Desirability of Outcome Ranking) assessment

FAQ

  • What is benzylpenicillin procaine and how does it work? Benzylpenicillin procaine is a combination of benzylpenicillin (penicillin G) and procaine, which creates a depot formulation that releases the antibiotic slowly into the bloodstream. It works by interfering with bacterial cell wall synthesis, which ultimately leads to bacterial cell death. The procaine component slows the release of penicillin, allowing for less frequent dosing (typically once daily by intramuscular injection) compared to standard benzylpenicillin, which requires multiple daily doses.
  • What types of infections is benzylpenicillin procaine being used to treat in clinical trials? Clinical trials are investigating benzylpenicillin procaine for treating various infections, including sepsis in young infants, Staphylococcus aureus bacteremia, and serious bacterial infections in community settings. One major trial is examining its use in simplified antibiotic regimens for young infants with possible serious bacterial infections in settings where hospital care is frequently refused. Other trials are comparing it with flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections.
  • How is benzylpenicillin procaine administered in clinical trials? In clinical trials, benzylpenicillin procaine is typically administered as an intramuscular injection. The dosage varies depending on the condition being treated and the patient's age and weight. For example, in the trial for young infants with possible serious bacterial infections, procaine penicillin is given at a dose of 50,000 IU/kg by intramuscular injection once daily for 7 days. This administration route allows for extended release of the antibiotic, providing sustained blood levels over 24 hours.
  • How does benzylpenicillin procaine compare to other antibiotics in clinical trials? Clinical trials are comparing benzylpenicillin procaine with several other antibiotics, including flucloxacillin, amoxicillin, and gentamicin. In one trial for sepsis in young infants, researchers are evaluating if the combination of procaine penicillin and gentamicin is equivalent to other regimens like injectable gentamicin with oral amoxicillin. Another study is comparing benzylpenicillin (a related formulation) with flucloxacillin for penicillin-susceptible Staphylococcus aureus bacteremia, investigating whether benzylpenicillin might offer advantages due to its lower minimum inhibitory concentration.
  • What are the potential advantages of using benzylpenicillin procaine over other antibiotics? Potential advantages of benzylpenicillin procaine include its once-daily dosing (due to slow release from the injection site), which may improve treatment adherence in outpatient settings. Some research suggests that for certain bacteria like penicillin-susceptible Staphylococcus aureus, benzylpenicillin may have theoretical advantages over other anti-staphylococcal penicillins due to lower minimum inhibitory concentration (MIC) values and the ability to achieve higher levels of free non-protein-bound plasma drug concentrations. These properties might make it more effective against certain infections, though more definitive clinical evidence is needed.

Ongoing Clinical Trials on BENZYLPENICILLIN PROCAINE

  • Study comparing dalbavancin to standard antibiotic treatment for patients with periprosthetic joint infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Betamethasone Sodium Phosphate and Drug Combination for Pregnant Women with Preterm Premature Rupture of Membranes

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Benzylpenicillin Procaine: A formulation that combines benzylpenicillin (penicillin G) with procaine to create a depot preparation that slowly releases the antibiotic over time, allowing for once-daily dosing by intramuscular injection.
  • Intramuscular Injection: A method of administering medication by injecting it directly into muscle tissue, where it is absorbed into the bloodstream over time. Benzylpenicillin procaine is typically given via this route.
  • Possible Serious Bacterial Infection (PSBI): A clinical condition in infants characterized by signs that suggest a significant bacterial infection, which may include fever, poor feeding, lethargy, or other concerning symptoms that require antibiotic treatment.
  • Neonatal Sepsis: A blood infection that occurs in a baby younger than 90 days old. Early-onset neonatal sepsis is seen in the first week of life, while late-onset sepsis occurs between 8 and 89 days.
  • Penicillin-Susceptible Staphylococcus Aureus (PSSA): Strains of Staphylococcus aureus bacteria that remain sensitive to penicillin antibiotics. Approximately 20% of S. aureus bacteremia cases may be susceptible to penicillin.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium. Lower MIC values indicate greater potency of the antibiotic against that specific bacterium.
  • International Units (IU): A unit of measurement for the quantity of a substance, based on measured biological activity or effect. Benzylpenicillin procaine doses are often expressed in IU/kg.
  • Randomized Controlled Trial (RCT): A type of scientific experiment that aims to reduce bias when testing a new treatment. Participants are randomly allocated to either the group receiving the treatment under investigation or to a group receiving standard treatment or placebo.
  • Equivalence Trial: A clinical trial designed to show that two treatments are equally effective (or ineffective) within a predefined margin of clinical difference.
  • Treatment Failure: The primary outcome measure in many antibiotic trials, defined as persistence or worsening of symptoms, need for additional antibiotics, hospital readmission, or death related to the infection being treated.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. PK studies help determine optimal dosing regimens.
  • Epithelial Lining Fluid (ELF): The fluid that lines the respiratory tract and is the site of infection in pneumonia. Some studies examine antibiotic concentrations in ELF to determine effectiveness for lung infections.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious complications including sepsis. S. aureus bacteremia is a common and serious form.
  • DOOR (Desirability of Outcome Ranking): A novel method for outcome analysis in clinical trials where participants are classified according to outcomes using ordinal categories, taking into account both benefits and risks of treatment.

References

  1. https://clinicaltrials.gov/study/NCT01027429
  2. https://clinicaltrials.gov/study/NCT03612557
  3. https://clinicaltrials.gov/study/NCT04986254
  4. https://clinicaltrials.gov/study/NCT00189384
  5. https://clinicaltrials.gov/study/NCT03632642
  6. https://clinicaltrials.gov/study/NCT06877351
  7. https://clinicaltrials.gov/study/NCT04876131
  8. https://clinicaltrials.gov/study/NCT04053140